Can Branched Chain Amino Acids Supplementation Reduce Muscle Damage Induced by Neuromuscular Electrical Stimulation? A Combined Functional and Metabolic Non-invasive Investigation in Healthy Humans
NCT ID: NCT01687361
Last Updated: 2014-09-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2012-06-30
2014-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Over the last decade, many studies paid attention to branched-chain amino acids (BCAA) supplementation as a potential prophylactic/therapeutic approach. The rationale of this approach is that BCAA might increase protein synthesis and reduce protein breakdown through physiological mechanisms involving mTOR regulation pathway (mammalian Target of Rapamycin). Additionally, BCAA could also be used as energetic substrate during exercise when glycogen stores are depleted. Overall, previous results have supported the efficacy of BCAA supplementation in attenuating muscle damage. Nevertheless, comprehensive studies investigating the effect of amino acid supplementation on markers of muscle damage are still scarce.
Magnetic resonance imaging (IRM) and phosphorus 31 magnetic resonance spectroscopy (31P-MRS) are powerful non invasive tools allowing the exploration of skeletal muscle structure and energy metabolism.
This ambitious project is devoted to the anatomical, functional and metabolic characterization of BCAA supplementation after NMES using MRI and 31P-MRS. Various markers of muscle damage, including maximal voluntary force production, T2 values and apparent diffusion coefficient (obtained by MRI) and energy metabolism assessed at rest and during exercise (using 31P-MRS), will be obtained before and after NMES. This project is of utmost importance for improving our knowledge of anatomic, metabolic and functional events related to BCAA supplementation in the context of exercise-induced muscle damage
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Branched-chain Amino Acid Supplementation on Muscle Damage
NCT03766815
Branched Chain Amino Acid Plus Glucose Supplement Reduces Exercise-Induced Delayed Onset Muscle Soreness in College Females
NCT01781910
The Effect of Branched-Chain Amino Acid Supplementation and Exercise on Body Composition During Energy Restriction
NCT02630238
Exercise-induced Muscle Damage is Reduced in Resistance Trained Athletes by Branch Chain Amino Acids
NCT01529281
Branched-chain Amino Acids Supplementation and Resistance Exercise-induced Muscle Damage and Inflammation
NCT01305018
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
branched-chain amino acids (BCAA) supplementation
branched-chain amino acids (BCAA) supplementation
PLACEBO
PLACEBO
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
branched-chain amino acids (BCAA) supplementation
PLACEBO
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between 18 and 35 years
* Subjects will have to be unhurt:
* Any general disease
* Psychiatric disorders(confusions)
* Any infectious, inflammatory, tumoral, vascular, degenerative or traumatic pathology
* They will have to follow no chronic treatment
* They will have to be unhurt of any history of alcoholism or drug addiction
Exclusion Criteria
* Suffering from claustrophobia
* Having stimulating one cardiac, carriers of a system Holter, carriers of hook(staple) (clip) surgical metallic, carriers of a prosthesis or a metallic implant (or quite other metallic foreign bodies), carriers of a prosthesis dental (device), carriers of a hearing aid, carriers of an insulin pump
* Having been hurt by pieces of shrapnel or lead
* Having had a dislocation, a fracture or a recent surgical operation (less than 6 months before the inclusion)
* Having followed a treatment with anti-inflammatory drugs during the last 3 months
* Having followed a treatment with amino acids during the last 3 months
* Having followed a treatment(processing) with anabolic steroids during the last 3 months
* Having participated in a program of body-building of lower limbs during the last 6 months
18 Years
35 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique Hopitaux De Marseille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
BERNARD BELAIGUES
Role: STUDY_DIRECTOR
Assistance Publique hĂ´pitaux de Marseille
jean pierre mattei
Role: PRINCIPAL_INVESTIGATOR
AP HM
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assistance Publique Hopitaux de Marseille
Marseille, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-04
Identifier Type: OTHER
Identifier Source: secondary_id
2012-A00449-34
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.